Palatin Technologies (PTN) Current Deferred Revenue (2011 - 2018)
Palatin Technologies' (PTN) quarterly Current Deferred Revenue came in at $500000.0 in Q2 2018, down 98.57% on a YoY basis from $35.1 million in Q2 2017, and down 14.61% quarter-over-quarter from $585519.0 in Q1 2018.
Powered by 
Analysis
Palatin Technologies (PTN) Current Deferred Revenue (2011 - 2018) Analysis & Trends
Palatin Technologies (PTN) has reported Current Deferred Revenue for 4 consecutive years, with $500000.0 the latest figure, recorded in Q2 2018.
- For the quarter ending Q2 2018, Current Deferred Revenue fell 98.57% year-over-year to $500000.0; the trailing twelve-month figure through Jun 2018 stood at $500000.0 (down 98.57% YoY), and the FY2018 full-year result was $500000.0, down 98.57% from the prior year.
- Current Deferred Revenue eased to $500000.0 in Q2 2018 per PTN's latest filing, from $585519.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $53.8 million in Q1 2017 and bottomed at $500000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 500,000.00 |
| Mar 31, 2018 | 585,519.00 |
| Dec 31, 2017 | 9.55 Mn |
| Sep 30, 2017 | 20.16 Mn |
| Jun 30, 2017 | 35.05 Mn |
| Mar 31, 2017 | 53.83 Mn |
| Jun 30, 2012 | 37,217.00 |
| Dec 31, 2011 | 7,396.00 |
| Sep 30, 2011 | 18,888.00 |
| Jun 30, 2011 | 391,817.00 |